Study Purpose: This clinical trial tests if a drug called CIN-102 (deudomperidone) can help adults with diabetic gastroparesis feel better. Diabetic gastroparesis is when the stomach doesn't empty food properly due to diabetes.

Study Process: Participants will have 1-2 screening visits, one lead-in visit, and will take a test called a Gastric Emptying Breath Test (GEBT). They will keep a daily diary and report symptoms. Over 12 weeks, they'll take CIN-102 or a placebo twice daily and visit the study site 7 times. One week after, there is a follow-up visit.

Key Points:

• The study lasts for about 14 weeks, including treatment and follow-up.
• Participants will have a total of 9-11 visits.
• There may be risks as with any clinical study, but the goal is to ensure safety.

Eligibility: You must be 18 years or older, have Type 1 or Type 2 diabetes, and a condition called diabetic gastroparesis. Some conditions like recent surgeries or severe heart problems may exclude you from joining.